Tempest Therapeutics
TPST
47 hedge funds and large institutions have $27.9M invested in Tempest Therapeutics in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 11 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
11% less capital invested
Capital invested by funds: $31.3M → $27.9M (-$3.41M)
13% less funds holding
Funds holding: 54 → 47 (-7)
20% less call options, than puts
Call options by funds: $4K | Put options by funds: $5K
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$1.18M |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
+$1.17M |
| 3 |
BC
Broadfin Capital
New York
|
+$402K |
| 4 |
DMK
David M. Knott
|
+$180K |
| 5 |
D.E. Shaw & Co
New York
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.96M |
| 2 |
Legal & General Group
London,
United Kingdom
|
-$713K |
| 3 |
ECM
Element Capital Management
New York
|
-$188K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$180K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$176K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAM
51
Panagora Asset Management
Boston,
Massachusetts
| $1K | – | – | – |
|
|
RE
52
RBC Europe
London,
United Kingdom
| $142 | – | – | – |
|
|
53
Legal & General Group
London,
United Kingdom
| – | -$713K | -157 | Closed |
|
|
PP
54
Paloma Partners
Greenwich,
Connecticut
| – | -$180K | -39 | Closed |
|
|
55
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$176K | -39 | Closed |
|
|
LP
56
LMR Partners
London,
United Kingdom
| – | -$145K | -32 | Closed |
|
|
ZIM
57
Zacks Investment Management
Chicago,
Illinois
| – | -$140K | -31 | Closed |
|
58
Goldman Sachs
New York
| – | -$129K | -28 | Closed |
|
|
IG
59
ING Group
Amsterdam,
Netherlands
| – | -$57K | -13 | Closed |
|
60
Jane Street
New York
| – | -$23K | -5 | Closed |
|
|
WS
61
Wedbush Securities
Los Angeles,
California
| – | -$19K | -4 | Closed |
|
|
GCP
62
GSA Capital Partners
London,
United Kingdom
| – | -$16K | -3 | Closed |
|
63
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$1K | – | – |
|
TPST Hedge Fund Activity: Q3 2017 in Review
47 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2017, worth a combined $27.9M — down 11% from $31.3M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TPST and 5 opened new positions — a net loss of 6 holders — while 11 trimmed existing stakes and 12 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $1.18M. The largest seller was Fidelity Investments, cutting an estimated $1.96M.
- 47 institutional investors held Tempest Therapeutics (TPST) as of Q3 2017, down from 54 in Q2 2017.
- Funds reported $27.9M of Tempest Therapeutics stock for Q3 2017, down 11% quarter-over-quarter.
- 5 funds opened new Tempest Therapeutics positions in Q3 2017 and 11 closed out, a net change of -6 holders.
- The largest Tempest Therapeutics buyer in Q3 2017 was Avoro Capital Advisors, an estimated $1.18M added.
- The largest Tempest Therapeutics seller in Q3 2017 was Fidelity Investments, an estimated $1.96M sold.
Based on aggregated 13F filings for Q3 2017.